Researchers investigated whether MHC-I and MHC-II antigen presentation and the presence of endogenous cDC1s contribute to the efficacy of adjuvant-activated, tumor antigen–loaded cDC1 vaccines. See what they found in The JI: ow.ly/FZ8J50ZQ9K9.
The Journal of Immunology is an official journal of The American Association of Immunologists, journals.aai.org/jimmunol Editor-in-Chief: Gail A. Bishop, Ph.D.